MINERALYS THERAPEUTICS, INC. Net Fee Amt
MINERALYS THERAPEUTICS, INC. (MLYS) had Net Fee Amt of $20.71 thousand as of 2026-06-03, per its 424B5 filed 2026-06-03.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-06-03
- 2026-06-03: Net Fee Amt $20.71K.
| Period end | Net Fee Amt |
|---|---|
| 2026-06-03 | $20.71K 424B5 · filed 2026-06-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |